Orphan Drug Development

Orphan Drug Development
Product Description

Accelerating orphan drug development from candidate selection to commercial manufacture and supply.

With over 300 million people worldwide living with identified rare diseases, the development of new treatments to address these unmet clinical needs is an area of great interest in the pharmaceutical industry.

Despite improvements in regulatory support and commercial rewards for developing orphan drugs, difficulties remain for drug developers in bringing these medicines to market quickly; including limited R&D budgets, alongside an ever-evolving regulatory framework, challenging product development and clinical recruitment.

- Integrated capabilities and expertise- Pre-formulation and API characterisation
- Formulation and process development
- First-in-human clinical testing and acceleration into POC trials
- Bespoke clinical manufacturing and supply (Phase I-III) of drug products into patient trials
- Rapid scale-up and commercial manufacturing of low-volume products

Read more Show less

QUOTIENT SCIENCES LIMITED

  • GB
  • 2017
    On CPHI since
  • 500 - 999
    Employees
Company types
Academic/Research
Consultancy
Contract Service
Manufacturer/Innovator
View company profile
Categories
more categories Show less
Specifications
  • Supplied from
    United Kingdom; United States
More specifications Fewer specifications
Sales Markets
Show more Show less

QUOTIENT SCIENCES LIMITED

  • GB
  • 2017
    On CPHI since
  • 500 - 999
    Employees
Company types
Academic/Research
Consultancy
Contract Service
Manufacturer/Innovator
View company profile

More Products from QUOTIENT SCIENCES LIMITED (16)

  • Clinical Pharmacology

    Product Clinical Pharmacology

    When you are looking for a partner who is dedicated to Phase I trials and early clinical development, rely on Quotient Sciences for the experience and expertise to seamlessly deliver your studies with the highest quality service and speed. We accelerate your molecule from first-in-human to proof-of-concept...
  • Bioanaysis

    Product Bioanaysis

    Delivering rapid bioanalytical data in discovery – preclinical – clinical. Bioanalysis is a critical step in the drug development process.  At Quotient, we are experts in the development, validation, and application of bioanalytical assays.  
    Our dedicated team of bioanalytical chemists...
  • Data Sciences

    Product Data Sciences

    You need data rapidly to make crucial decisions during a study. Faster data means we can provide our customers with earlier interim data and interim PK reports for on-study dosing and formulation decisions.
    We understand on-study changes to early phase study designs and d...
  • Drug Development Consulting

    Product Drug Development Consulting

    Our Drug Development Consultants work with you to design and implement successful drug development programs. With industry leading scientific expertise across a range of technical disciplines, we help customers across all stages of development, from candidate selection to commercial launch.

    Our cons...
  • Global Clinical Trial Supply

    Product Global Clinical Trial Supply

    Accelerate your timeline, with flexible, on-demand delivery. We’ll design and develop your packaging, labelling and distribution strategy for Phase I, Phase II and Phase III clinical studies, so you’ll no longer have to worry about the challenge of getting your drug product to multiple sites in time fo...
  • Pediatric Development

    Product Pediatric Development

    Pediatric formulation and product development

    The development of acceptable, palatable pediatric formulations is a key feature within the industry today, driven by patient needs and regulatory requirements. Quotient Sciences has extensive knowledge and capabilities that enable us to provide you...
  • Inhaled Drug Development

    Product Inhaled Drug Development

    Quotient has a 30 year track record in the development and manufacturing of inhaled drug products. We have experience across a range of drug delivery platforms including dry powder inhalers (DPIs) and solutions/suspensions for inhalation. With integrated capabilities and vast knowledge of nasal and pu...
  • Translational Pharmaceutics - Integrated Programs

    Product Translational Pharmaceutics - Integrated Programs

    Translational Pharmaceutics® accelerates drug development by integrating formulation development, real-time manufacturing and clinical testing. The platform is unique to Quotient Sciences and has been used over the last decade by global pharmaceutical and biotech companies across over 400 drug programs. qq...
  • Oncology

    Product Oncology


    Supporting oncology drug development from candidate selection through to commercial manufacture and supply
    In the past 5 years alone, Quotient has successfully worked on over 300 oncology development projects for 91 different oncology drug candidates spanning 34 different disea...
  • Candidate Selection - Integrated Programs

    Product Candidate Selection - Integrated Programs

    Selecting the right molecules for development - Quickly identify the best drug candidates. Knowing what it takes to develop a successful drug, we help clients select the best molecules for development. Our unique integration of scientific capabilities enables us to provide a complete assessment o...
  • Early Stage Development - Integrated Programs

    Product Early Stage Development - Integrated Programs

    Accelerating molecules through to proof-of-concept - Simplify early development and accelerate to Proof-of Concept.Proof-of-concept (POC) is a key milestone in the development of a new drug candidate. We understand the transition to POC needs to be fast and cost-effective.With fully integrated capabil...
  • Late Stage Development - Integrated Programs

    Product Late Stage Development - Integrated Programs

    .Accelerating products through to commercial manufacture - Speed the journey from proof-of-concept to commercial launch. The journey from proof-of-concept to commercial launch can be complex. Speed is critical but it shouldn’t come at the expense of product quality. Creating patient-centric formulatio...
show all 16 other products

QUOTIENT SCIENCES LIMITED resources (2)

  • Quotient Sciences acquires UK-based CDMO Arcinova

    News Quotient Sciences acquires UK-based CDMO Arcinova

    With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide
    9 Mar 2021
  • Formulation Development at Quotient

    Technical Data Formulation Development at Quotient

    Quotient Sciences has almost 30 years of experience developing a breadth of pharmaceutical formulations across a range of indications. Our innovative approach to formulation development integrates drug product development with clinical evaluation, combined with our experience with over 1,000 molecules at all stages of drug development.